Check the time stamp on this data. Updated AI-Generated Signals for Nurix Therapeutics Inc. (NRIX) available here: NRIX. Type ...

Investors in Nurix Therapeutics Inc (Symbol: NRIX) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat ...

NRIX opened at $19.68 on Tuesday. The firm has a market capitalization of $1.39 billion, a P/E ratio of -6.76 and a beta of 2.14. The firm’s 50 day moving average is $20.65 and its 200-day ...

In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price ...

Nurix Therapeutics (NRIX) announced the appointment of John Northcott as chief commercial officer. From 2022 through 2024, Mr. Northcott served ...

SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat ...

Nurix Therapeutics, Inc. has appointed John Northcott as its new chief commercial officer, bringing over 20 years of experience in biotechnology commercialization. His background includes ...

NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of John ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...

SAN FRANCISCO - Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in targeted protein modulation drugs, announced today the appointment of John Northcott as its new ...